XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
G
G

Gilead

市场新闻

Reuters - 1周前

U.S. STOCKS Unity Software, Viking Holdings, Adobe

BUZZ-U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed in choppy trading on Thursday after higher-than-expected producer prices data kept a smaller 25-basis point rate cut by the Fed firmly on the table, while Moderna slumped following a downbeat revenue forecast.
A
G
K
M
U
U
U
D
A
Reuters - 1周前

U.S. STOCKS Gold miners, silver miners, Warner Bros Discovery

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was little changed on Thursday after hot producer prices data kept a smaller, 25-basis-point interest-rate cut by the Federal Reserve firmly on the table, while vaccine maker Moderna's shares slumped following a downbeat revenue forecast.
G
K
M
U
U
D
W
A
Reuters - 1周前

Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada

BUZZ-Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada ** Shares of drugmaker Gilead GILD.O rise nearly 2% to $82.55 ** Co says its HIV injectable drug lenacapavir reduced HIV infections by 96% and was superior to daily pill Truvada in second late-stage trial ** The study included cisgender men, transgender men, tra
G
Reuters - 1周前

U.S. Cintas, Sprouts Farmers Market, Voya Financial

U.S. RESEARCH ROUNDUP-Cintas, Sprouts Farmers Market, Voya Financial Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thursday. HIGHLIGHTS * Ally Financial Inc ALLY.N : RBC cuts target price to $40 from $49 * Cintas Corp CTAS.O : CFRA adjusts target price to $170 from $645 to reflect 4-for-1 stock split * Gilead GILD.O : Raymond James raises target pri
C
E
G
L
N
P
S
E
A
D
E
L
Reuters - 1周前

US FDA staff questions confirmatory trial data for Intercept's liver disease drug

UPDATE 2-US FDA staff questions confirmatory trial data for Intercept's liver disease drug Rewrites paragraph 1, adds details from FDA and company's briefing documents in paragraphs 7, 8 and 9 and background in paragraphs 10 and 11 Sept 11 (Reuters) - Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the effectiveness of Intercept's liver disease drug, which received the health regulator's accelerated nod in 2016. Under the accelerated p
G
Reuters - 3周前

U.S. Centerspace, Neurocrine Biosciences, 1-800-Flowers.com

U.S. RESEARCH ROUNDUP-Centerspace, Neurocrine Biosciences, 1-800-Flowers.com Aug 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Neurocrine Biosciences and Veeva Systems, on Thursday. HIGHLIGHTS * Air Products APD.N : Berenberg raises target price to $275 from $240 * Centerspace CSR.N : Raymond James raises target price to $82 from $75 * Neurocrine Biosciences Inc NBIX.O : Piper Sandler raises to over
A
G
M
N
N
S
A
D
E
E
A
E
P
Reuters - 3周前

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +2.0% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% Copart Inc CPRT.OQ +1.2% Verisk Analytics Inc VRSK.OQ +1.2% Old Dominion Freight Line Inc ODFL.OQ +1.1% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -25.1% PDD Holdings Inc PDD.OQ -6.3% Arm Holdings PLC ARM.OQ -5.5% Lululemon Athletica Inc LULU.OQ -4.4% Micron Technology Inc MU.OQ -4.3%
G
L
M
V
V
U
P
C
O
Reuters - 3周前

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Insulet Corp PODD.OQ +3.9% Bristol-Myers Squibb Co BMY.N +2.9% Bio Rad Laboratories Inc BIO.N +2.1% Gilead Sciences Inc GILD.OQ +2.0% International Flavors & Fragrances Inc IFF.N +1.9% Bottom Performers Percent Change Super Micro Compu
G
L
M
U
I
Reuters - 3周前

U.S. Alamo Group, Cognizant, Moderna

CORRECTED-U.S. RESEARCH ROUNDUP- Alamo Group, Cognizant, Moderna Corrects ESS Tech Inc entry to say Deutsche Bank adjusts PT to $9 from $0.90 to reflect 1-for-15 reverse stock split Aug 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alamo Group, Cognizant and Moderna, on Wednesday.
C
G
M
S
U
C
E
P
Reuters - 1个月前

PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI®

BRIEF-PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI® Aug 16 (Reuters) - PANTHERx Rare Pharmacy- PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI®
G
Reuters - 1个月前

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.
B
G
I
N
Reuters - 1个月前

U.S. Allstate, bluebird bio , Vicinity Motor

U.S. RESEARCH ROUNDUP-Allstate, bluebird bio , Vicinity Motor Aug 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, bluebird bio and Vicinity Motor, on Thursday. HIGHLIGHTS * Allstate Corp ALL.N : CFRA cuts to hold from buy * Autodesk Inc ADSK.O : Baird raises target price to $295 from $289 * bluebird bio Inc BLUE.O : JP Morgan cuts to neutral from overweight * Provident Financial Services Inc PFS.N : KBW
A
A
C
G
I
K
D
A
Reuters - 1个月前

Gilead gets US FDA approval for inflammatory liver disease drug

UPDATE 3-Gilead gets US FDA approval for inflammatory liver disease drug Adds pricing in paragraph 4, company comments in paragraphs 6-7, details on common symptom in paragraphs 10-12 By Puyaan Singh and Leroy Leo Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year.
G
I
Reuters - 1个月前

FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website

BRIEF-FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website Aug 14 (Reuters) - FDA: FDA APPROVES GILEAD'S LIVDELZI FOR PRIMARY BILIARY CHOLANGITIS - WEBSITE Further company coverage: GILD.O
G
Reuters - 1个月前

US FDA approves Gilead's liver disease drug

US FDA approves Gilead's liver disease drug Aug 14 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' GILD.O drug for a chronic and potentially fatal liver disease that mostly affects women. The disease, primary biliary cholangitis (PBC), causes inflammation of the small bile ducts in the liver and can eventually destroy them.
G
Reuters - 1个月前

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary Gilead Sciences Inc GILD.OQ reported quarterly adjusted earnings of $2.01​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.66. The mean expectation of twenty three analysts for the quarter was for earnings of $1.60 per share.
G
Reuters - 1个月前

Gilead quarterly profit beats Street estimates, revenue up 5%

UPDATE 1-Gilead quarterly profit beats Street estimates, revenue up 5% Adds analyst comment, share price, paragraphs 4-6 By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
G
Reuters - 1个月前

Gilead quarterly profit beats Street estimates, revenue up 5%

Gilead quarterly profit beats Street estimates, revenue up 5% By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings. The Foster City, California-based company posted a quarterly profit of $2.01 per share excluding items, on revenue of $7 billion, up from $1.34 a share and revenue of $6.6 bi
G
Reuters - 1个月前

Gilead Q2 EPS USD 1.29

BRIEF-Gilead Q2 EPS USD 1.29 Aug 08 (Reuters) - Gilead Q2 product sales USD 6,912 million. Q2 operating income USD 2,644 million Q2 pretax profit USD 2,053 million vs. IBES estimate USD 2,593 million Q2 net income USD 1,614 million Q2 basic EPS USD 1.29
G
Reuters - 1个月前

Merck stops testing combo drug for lung cancer

UPDATE 1-Merck stops testing combo drug for lung cancer Adds details in paragraphs 2 and 6, background throughout Aug 8 (Reuters) - Merck MRK.N said on Thursday it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed. The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck sa
G

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。